Hyperglycemia Common in HR+ Breast Cancer Patients Treated with PI3K and AKT Inhibitors

Researchers are reporting that hyperglycemia, or high blood sugar, frequently occurs as a negative side effect when using PI3K and AKT inhibitors to treat hormone receptor-positive (HR+) breast cancer. The study indicates that PI3K and AKT inhibitors, which are therapies targeting specific cellular pathways in cancer cells, often lead to elevated blood sugar levels in patients with HR+ breast cancer. This adverse effect is significant because it is common among patients.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Author

Mark Chiang